<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511728</url>
  </required_header>
  <id_info>
    <org_study_id>HSK3486-306</org_study_id>
    <nct_id>NCT04511728</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of HSK3486 in the Induction of General Anesthesia</brief_title>
  <official_title>A Multi-center, Randomized, Single-blind, Propofol Injectable Emulsion Parallel-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK3486 Injectable Emulsion in the Induction of General Anesthesia in Patients Undergoing Elective Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haisco Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haisco Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, randomized, single-blind, propofol injectable emulsion&#xD;
      parallel-controlled Phase III clinical study. A total of patients undergoing elective surgery&#xD;
      are intended to be enrolled and randomly assigned to HSK3486 group and propofol group in a&#xD;
      2:1 ratio.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 25, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success rate of anesthesia maintenance</measure>
    <time_frame>During maintenance of general anesthesia on day 1</time_frame>
    <description>During the maintenance of anesthesia, the subject is not recovered and no remedial anesthetic is used</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>Pre-dose to 48 hours post-dose</time_frame>
    <description>Safety endpoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of anesthesia induction</measure>
    <time_frame>During induction of general anesthesia on day 1</time_frame>
    <description>During the induction of anesthesia, the subject achieves successful induction (i.e., MOAA/S ≤ 1) after administration of the study drug (up to 2 top-up doses), and no remedial anesthetic is used.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of time from the beginning of surgical skin incision to the end of surgery</measure>
    <time_frame>During maintenance of general anesthesia on day 1</time_frame>
    <description>when bispectral index (BIS) is ≥ 40 and ≤ 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery from anesthesia</measure>
    <time_frame>A period of time from discontinuation of the study drug to recovery after the end of surgery on day 1</time_frame>
    <description>3 consecutive MOAA/S = 5. Record the time when MOAA/S = 5 is reached for the first time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to respiratory recovery</measure>
    <time_frame>A period of time from discontinuation of the study drug to respiratory recovery after the end of surgery on day 1</time_frame>
    <description>Respiratory rate ≥ 8 breaths/min and the tidal volume ≥ 5 mL/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from discontinuation of the study drug to 3 consecutive Aldrete score ≥ 9.</measure>
    <time_frame>A period of time from discontinuation of the study drug to 3 consecutive Aldrete score ≥ 9 on day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Induction and Maintenance of General Anesthesia</condition>
  <arm_group>
    <arm_group_label>HSK3486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HSK3486</intervention_name>
    <description>The initial Induction dose of HSK3486 is 0.4 mg/kg. The initial maintenance dose of HSK3486 is 0.8 mg/kg/h</description>
    <arm_group_label>HSK3486</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>The initial Induction dose of propofol is 2.0 mg/kg. The initial maintenance dose of propofol is 5.0 mg/kg/h</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. In-patients undergoing non-emergency, non-cardiothoracic, and non-extracerebral&#xD;
             elective surgeries with expected operation time ≥ 1 h and requiring tracheal&#xD;
             intubation under general anesthesia (patients whose surgery type may affect the&#xD;
             collection of BIS parameter should not be included);&#xD;
&#xD;
          2. Male or female, age ≥ 18 and ≤ 65 years old;&#xD;
&#xD;
          3. American Society of Anesthesiologists (ASA) class I-III;&#xD;
&#xD;
          4. Body mass index (BMI) ≥ 18 and ≤ 30 kg/m^2;&#xD;
&#xD;
          5. Vital signs in the screening period meeting the following criteria:&#xD;
&#xD;
               1. Respiration rate ≥ 10 and ≤ 24 breaths/min;&#xD;
&#xD;
               2. SpO2 while breathing ≥ 95%;&#xD;
&#xD;
               3. Systolic blood pressure ≥ 90 mmHg and ≤ 160 mmHg;&#xD;
&#xD;
               4. Diastolic blood pressure ≥ 60 mmHg and ≤ 100 mmHg;&#xD;
&#xD;
               5. Heart rate ≥ 55 and ≤ 100 bpm. (Note: The heart rate is judged by the results of&#xD;
                  ECG monitoring after signing the ICF, and the heart rate results of 12-lead ECG&#xD;
                  examination are not used as the basis for judgment.)&#xD;
&#xD;
          6. Subjects must understand the procedures and methods of this study, and be willing to&#xD;
             provide informed consent and to complete the trial in strict accordance with study&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with contraindications to general anesthesia or previous history of&#xD;
             anesthesia accidents;&#xD;
&#xD;
          2. Known hypersensitivity to excipients and ingredients found in propofol injection and&#xD;
             HSK3486 injectable emulsion (soybean oil, glycerin, triglycerides, egg lecithin,&#xD;
             sodium oleate, and sodium hydroxide), benzodiazepines, opioids, rocuronium bromide,&#xD;
             and sugammadex sodium; cross-reactivity to halogenated anesthetics, jaundice or&#xD;
             unexplained fever from previous use of halogenated anesthetics; contraindications to&#xD;
             propofol;&#xD;
&#xD;
          3. The following disease history or evidence that increases the risk of&#xD;
             sedation/anesthesia is collected before/during screening:&#xD;
&#xD;
               1. History of cardiovascular diseases: uncontrolled hypertension or SBP &gt; 160 mmHg&#xD;
                  and/or DBP &gt; 100 mmHg after treatment with antihypertensive drugs, severe&#xD;
                  arrhythmia, heart failure, Adams-Stokes syndrome, unstable angina, myocardial&#xD;
                  infarction, tachycardia/bradycardia requiring medication, or third-degree&#xD;
                  atrioventricular block within 6 months before screening, or QTcF interval of ≥&#xD;
                  450 ms (corrected using Fridricia's formula) during the screening period;&#xD;
&#xD;
               2. History of respiratory diseases: respiratory insufficiency, history of&#xD;
                  obstructive pulmonary disorders, history of bronchospasm requiring treatment&#xD;
                  within 3 months before screening, and acute respiratory infection with one of the&#xD;
                  symptoms such as obvious fever, wheezing or productive cough within 1 week before&#xD;
                  the baseline period;&#xD;
&#xD;
               3. History of neurological and psychiatric disorders: craniocerebral injury,&#xD;
                  convulsions, epilepsy, intracranial hypertension, cerebral aneurysms,&#xD;
                  cerebrovascular accidents; or schizophrenia, mania, long-term use of psychotropic&#xD;
                  drugs, history of cognitive impairment, etc.;&#xD;
&#xD;
               4. History of gastrointestinal tract diseases: gastrointestinal retention, active&#xD;
                  bleeding, gastroesophageal reflux or obstruction, etc. which may cause reflux and&#xD;
                  aspiration judged by the investigator;&#xD;
&#xD;
               5. Diabetic patients with uncontrolled blood glucose (fasting blood glucose ≥ 11.1&#xD;
                  mmol/L, and/or random blood glucose ≥ 13.6 mmol/L);&#xD;
&#xD;
               6. Patient with a history of uncontrolled and clinically significant liver, kidney,&#xD;
                  blood system, nervous system or metabolic system diseases judged by the&#xD;
                  investigator to be unsuitable for this trial;&#xD;
&#xD;
               7. History of alcohol abuse within 3 months prior to screening, where alcohol abuse&#xD;
                  refers to daily alcohol drinking &gt; 2 units of alcohol (1 unit = 360 mL of beer or&#xD;
                  45 mL of liquor with 40% alcohol or 150 mL of wine);&#xD;
&#xD;
               8. History of drug abuse within 3 months prior to screening;&#xD;
&#xD;
               9. Serious infection, trauma, or major surgery within 4 weeks prior to screening.&#xD;
&#xD;
          4. Any of the following respiratory management risks before/during screening:&#xD;
&#xD;
               1. Asthma history and stridor;&#xD;
&#xD;
               2. Sleep apnea syndrome;&#xD;
&#xD;
               3. History or family history of malignant hyperthermia;&#xD;
&#xD;
               4. History of intubation failure;&#xD;
&#xD;
               5. Judged by the investigator to have difficult airway or judged as difficult&#xD;
                  tracheal intubation (modified Mallampati score III or IV).&#xD;
&#xD;
          5. In receipt of any of the following drugs or therapies prior to screening:&#xD;
&#xD;
               1. Participated in other clinical drug trials within 1 month prior to screening;&#xD;
&#xD;
               2. Used drugs that may affect QT intervals within 2 weeks prior to screening;&#xD;
&#xD;
               3. In receipt of propofol, other general sedatives/anesthetics, and/or opioid&#xD;
                  analgesics or compounds containing opioid analgesics within 3 days prior to&#xD;
                  screening.&#xD;
&#xD;
          6. Patient whose laboratory test results measured at screening reach the following&#xD;
             criteria and are verified through re-examination:&#xD;
&#xD;
               1. Neutrophil count ≤ 1.5 × 10^9/L;&#xD;
&#xD;
               2. Platelet count &lt; 80 × 10^9/L;&#xD;
&#xD;
               3. Hemoglobin &lt; 90 g/L (no blood transfusion within the last 14 days);&#xD;
&#xD;
               4. Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) &gt; 3.0 ×&#xD;
                  ULN;&#xD;
&#xD;
               5. Total bilirubin &gt; 2 × ULN;&#xD;
&#xD;
               6. Blood creatinine &gt; 1.5 × ULN.&#xD;
&#xD;
          7. Women who are pregnant or breastfeeding; women of child-bearing potential or men who&#xD;
             are unwilling to use contraception method during the trial; subjects who are planning&#xD;
             pregnancy within 3 months after the completion of the trial (including male subjects);&#xD;
&#xD;
          8. Subjects judged by the investigator to be unsuitable for participating in this trial&#xD;
             for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Liu xiao</last_name>
    <phone>15921176768</phone>
    <email>liux1@haisco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Hospital，Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wang xiao</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

